Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and is expanding its neuropsychiatry business, particularly with Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy emphasizes the growth of its commercial portfolio, with Jornay PM as the primary growth driver, and aims to deploy capital in a disciplined manner [3].

Core Points - Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary as a publicly traded company by ringing the Nasdaq opening bell on October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD, which is now the fastest growing stimulant medicine for ADHD [2] - Collegium's strategy focuses on growing its commercial portfolio, with Jornay PM as the primary growth driver, while maintaining a disciplined approach to capital deployment [3] Company Overview - Collegium is a diversified biopharmaceutical company dedicated to improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company is headquartered in Stoughton, Massachusetts, and aims to continue making a positive impact in the healthcare community [3]

Core Insights - Collegium Pharmaceutical, Inc. is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market, with a bell-ringing ceremony scheduled for October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM® for ADHD, which is now the fastest growing stimulant medicine for ADHD treatment [2][3] Company Overview - Collegium is focused on building a diversified biopharmaceutical company aimed at improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company's strategy includes expanding its commercial portfolio, with Jornay PM as the primary growth driver, and managing capital deployment in a disciplined manner [3]

Core Insights - Collegium Pharmaceutical, Inc. will present nine posters at PAINWeek 2025, showcasing real-world data from its pain management portfolio, emphasizing its commitment to responsible pain management [1][42] - The poster session is scheduled for September 4, 2025, from 4 – 5:30 p.m. PT, aimed at providing healthcare professionals with insights to support clinical decision-making [2] Group 1: Research Presentations - The posters will include analyses on the treatment characteristics and safety of Belbuca and other opioid treatments among chronic low back pain patients [3] - Specific studies will cover the economic burden of transitioning patients from short-acting opioids to Belbuca, as well as the safety profiles of these medications [3][5] - Additional research will focus on opioid use disorder outcomes and clinical outcomes translated to healthcare costs [5][6] Group 2: Company Overview - Collegium is focused on building a diversified biopharmaceutical company with a strong portfolio in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM [42] - The company's strategy includes growing its commercial portfolio, with Jornay PM identified as a key growth driver [42]

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its second quarter 2025 financial results on August 7, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM, a treatment for ADHD, marking its entry into neuropsychiatry [3]. - Collegium's growth strategy emphasizes expanding its commercial portfolio, with Jornay PM identified as the primary growth driver, while maintaining disciplined capital deployment [3].

Financial Performance and Guidance - Collegium reported 2024 sales of $631 million and expects 2025 sales to reach $743 million, representing an +18% increase[16] - The company anticipates 2025 net product revenues in the range of $735 million to $750 million, reflecting an +18% year-over-year growth[22] - Adjusted EBITDA for 2025 is projected to be between $435 million and $450 million, a +10% increase[22] - Adjusted operating expenses for 2025 are expected to be in the range of $220 million to $230 million, a +49% increase[22] Product Portfolio and Market Position - Jornay PM net revenue is expected to exceed $135 million in 2025, representing a +>34% increase from $100.7 million in 2024[40] - The pain portfolio experienced a +5% revenue growth in 2024, while total revenue grew +11%[20] - Q1 2025 pain portfolio product revenues reached $177.8 million, a +23% increase compared to $144.9 million in Q1 2024[32] - Jornay PM prescriptions grew +24% year-over-year in Q1 2025[32] Capital Allocation and Shareholder Value - Collegium initiated a $25 million Accelerated Share Repurchase (ASR) program in May 2025[33] - The company repurchased $222 million worth of shares between 2021 and 2025[47] Debt and Cash Flow - The company had approximately $200 million in cash and marketable securities at the end of Q1 2025[27] - Net debt to adjusted EBITDA stood at approximately 1.5x at the end of Q1 2025[33]

Summary of Collegium Pharmaceutical (COLL) Conference Call Company Overview - Collegium Pharmaceuticals is focused on building a diversified biopharmaceutical company, primarily addressing chronic pain and ADHD [2][3] - The company generated $631 million in net sales in 2024, with an expected growth of 18% to $743 million in 2025 [3][9] Product Portfolio - The company has five marketed products, including: - **Jornay PM**: $100 million in net sales in 2024, expected to exceed $135 million in 2025. It is the only ADHD medicine with once-daily evening dosing [5][6] - **BELBUCA**: $211 million in net sales in 2024, a long-acting opioid using buprenorphine buccal film technology [7] - **Xtampza ER**: $191 million in net sales in 2024, an extended-release oxycodone with abuse deterrent technology [8] - **Nucynta Franchise**: $177 million in net sales in 2024, treating severe and persistent pain as well as neuropathic pain [8] Financial Performance - Expected net revenues for 2025 are between $735 million and $750 million, indicating an 18% year-over-year growth [9] - Adjusted EBITDA is projected to be between $435 million and $450 million, representing a 10% year-over-year growth [10] - Adjusted operating expenses are expected to grow by 49% year-over-year due to the acquisition of Ionshore Therapeutics [10] Revenue Durability - The company has a strong expectation of revenue durability, with projected exclusivity for Xtampza ER through September 2033 and BELBUCA until January 2027 [14][15] - No generic competitors have satisfied all criteria to launch future generics, which supports the durability of the pain portfolio [17] Recent Business Highlights - In Q1 2025, the company achieved $177 million in net sales, a 23% increase from 2024 [18] - Cash from operations was over $55 million, with a leverage ratio of 1.5 net debt over EBITDA, expected to decrease to less than 1 by the end of 2025 [19] - A share repurchase program of $25 million was announced in May 2025 [19] Growth Strategies - The company is investing in Jornay PM to maximize growth and has expanded its sales team from 125 to 180 representatives [21][22] - Marketing programs are being implemented to raise awareness among caregivers and patients, aligning with the back-to-school season [23] Competitive Positioning - Collegium is positioned uniquely among biopharmaceutical peers with a robust revenue profile and double-digit growth [25] - The company has a strong cash generation profile and a history of returning value to shareholders, having repurchased $222 million in shares since 2021 [26][27] - The majority of its medicines are sourced and sold in the US, making them largely immune to tariffs and pricing pressures [28] Conclusion - Collegium Pharmaceuticals is well-positioned for continued growth, with a strong focus on revenue generation, profitability, and disciplined capital deployment strategies [28]

Financial Data and Key Metrics Changes - The company reported a 23% year-over-year revenue growth, with net product revenues reaching $177.8 million [27] - GAAP net income was $2.4 million, a decrease from $27.7 million in the first quarter of 2024, impacted by acquisition-related expenses [29] - Non-GAAP adjusted EBITDA was $95.2 million, up 3% year over year [29] - The cash position increased to $197.8 million, up $35 million from year-end [30] Business Line Data and Key Metrics Changes - The ADHD medicine Jornay generated $28.5 million in net revenue, with a 24% year-over-year growth in prescriptions [7][27] - The pain portfolio generated $149.2 million in sales, reflecting a 3% year-over-year growth, with all three pain medicines showing single-digit growth [9][22] - BELBUCA net revenue was $51.7 million, up 2% year over year; Xtampza net revenue was $47.6 million, up 4%; and Nucynta franchise net revenue was $47.1 million, also up 4% [28] Market Data and Key Metrics Changes - Jornay's market share in the long-acting branded methylphenidate market increased to 20.3%, up 6.4% year over year [19] - The overall ADHD market is growing at about 5% to 6% annually [48] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving growth in Jornay, maximizing the pain portfolio's value, and strategically deploying capital to enhance shareholder value [4][11] - The company aims to diversify its portfolio through disciplined business development and has authorized a $25 million accelerated share repurchase program [11][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the pain portfolio and its ability to generate significant cash flows [12][25] - The company is well-positioned to achieve its 2025 financial guidance and is focused on creating shareholder value [33] Other Important Information - The company completed the expansion of its ADHD sales force, adding approximately 55 new representatives, bringing the total to about 180 [9][20] - The company is undergoing leadership changes, with the founder retiring and new executives joining the team [10] Q&A Session Summary Question: How will Journey scripts trend as the school year ends? - Management noted that there is typically a slowdown in scripts towards the end of the school year, followed by an acceleration in the back-to-school season [36][38] Question: Is there potential to utilize JOURNEY PM technology for other compounds? - Management confirmed that discussions regarding the use of the technology for other compounds had occurred prior to the acquisition [40] Question: What is the appetite for business development deals? - Management indicated a disciplined approach to capital deployment, focusing on the right opportunities for business development while also prioritizing debt repayment and share repurchases [42][44] Question: What is the overall ADHD market growth? - The ADHD market is growing at about 5% to 6% annually [48] Question: What is the breakdown of the prescriber base for Jornay? - The prescriber base consists of approximately 40% pediatricians, 40% neuropsychiatrists, and the remaining 20% split between PCPs and mid-level providers [48] Question: What is the size of the sales organization contemplated for Jornay? - Management stated that the current sales force of 180 is appropriate for the target audience, with regular evaluations for potential adjustments [56]

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2 ...